EMERALD-3 Roundtable: Hepatocellular Carcinoma Trial Breakdown & Insights

MATTERHORN Roundtable: Perioperative FLOT & Immunotherapy Updates in Gastric Cancer

The treatment landscape for perioperative gastric cancer is changing rapidly.In this expert roundtable, leading GI oncology specialists discuss the practice-changing impact of the MATTERHORN trial, the role of immunotherapy in resectable gastric cancer, and how emerging data from ASCO 2026 is influencing treatment decisions in both academic and community settings.Featuring insights from Dr. Zev Wainberg, Dr. Nataliya Uboha, Dr. Sunnie Kim, Dr. Harry Menon, Dr. Angela Alistar, Dr. Raji Shameem, and Dr. Timothy Brown.Key topics discussed:• MATTERHORN trial results and clinical implications• Adding durvalumab to perioperative FLOT chemotherapy• Event-free survival and overall survival outcomes• Pathologic complete response (pCR) and major pathologic response (MPR)• The role of PD-L1 testing and biomarker selection• Interpreting subgroup analyses in gastric cancer• FLOT as the current perioperative standard of care• Immunotherapy in resectable gastric and gastroesophageal cancers• Global perspectives on gastric cancer treatment• Practical considerations for community oncologists• Future directions in perioperative upper GI cancer researchAs immunotherapy moves earlier into the treatment journey, clinicians are faced with new opportunities—and new questions—about patient selection, biomarkers, treatment sequencing, and long-term outcomes.Subscribe for more expert oncology discussions, clinical trial updates, and insights from leading cancer specialists.

EMERALD-3 Roundtable: Hepatocellular Carcinoma Trial Breakdown & Insights

Could EMERALD-3 redefine the treatment paradigm for unresectable hepatocellular carcinoma?In this special roundtable discussion recorded at ASCO 2026, Dr. Ghassan Abou-Alfa is joined by Dr. Gentry King, Dr. Mehmet Akce, Dr. Pierre Gholam, Dr. Lingling Du, Dr. Adam Burgoyne, Dr. Lipika Goyal, and Dr. Riad Salem to break down the landmark EMERALD-3 study.The panel explores the scientific rationale for combining transarterial chemoembolization (TACE) with immunotherapy and antiangiogenic therapy, while reviewing key efficacy findings from the EMERALD-3 study. Beyond the data, the experts discuss how locoregional therapies can enhance immune responses, and examine the practical challenges of patient selection, multidisciplinary decision-making, treatment sequencing, and the evolving role of interventional radiology in modern HCC management.Topics discussed include:• EMERALD-3 trial design and results• TACE plus systemic therapy in HCC• Durvalumab and immunotherapy strategies• Lenvatinib and antiangiogenic therapy• Synergy between embolization and immunotherapy• Locoregional therapy in unresectable HCC• Progression-free survival and clinical outcomes• Multidisciplinary management of liver cancer• Interventional radiology and oncology collaboration• Patient selection for combination therapy• Future directions in hepatocellular carcinoma treatment• How EMERALD-3 may influence clinical practiceAs treatment options continue to expand, understanding how systemic therapy and locoregional interventions work together may be key to improving outcomes for patients with liver cancer.Subscribe for more expert oncology discussions, clinical trial updates, and insights from leading cancer specialists.

Dr. Ursa Brown Glaberman & Dr. Karthik Giridhar- Managing Capiva-sertib & the AKT Path-way in 2L mBC

How are we navigating the evolving landscape of second-line treatment for metastatic HR-positive, HER2-negative breast cancer?In this full-length discussion, Dr. Ursa Brown-Glaberman and Dr. Karthik Giridhar explore one of the most rapidly evolving areas in breast oncology: treatment selection after progression on first-line endocrine therapy and CDK4/6 inhibitors.The conversation examines how molecular profiling, ctDNA testing, AKT pathway targeting,PIK3CA alterations, ESR1 mutations, and emerging biomarkers are reshaping decision-making in the second-line setting. The experts also discuss how they approach endocrine therapy sequencing, when to transition to ADCs, and how toxicity, quality of life, and patient preferences influence treatment selection.Topics discussed include:• Second-line treatment strategies in HR-positive metastatic breast cancer• Endocrine therapy sequencing after CDK4/6 inhibitors• ESR1 mutation testing and ctDNA monitoring• Tissue biopsy versus liquid biopsy• PIK3CA mutations and targeted therapies• Capivasertib versus alpelisib decision-making• AKT pathway inhibition in metastatic disease• Germline BRCA and PALB2 testing• Biomarker-driven treatment selection• When to transition from endocrine therapy to ADCs• Quality of life considerations in metastatic breast cancer• The future of personalized treatment sequencingAs the treatment landscape continues to expand, understanding how to personalize second-line therapy has become one of the most important challenges in modern breast cancer care.Subscribe for more expert oncology discussions, breast cancer treatment updates, and clinical insights from leading specialists.

Dr. Sarah Premji, Dr. Reshma Mahtani & Dr. Eleftherios Mamounas - Expanding T-DXd Across HER2 + Breast Cancer

How is trastuzumab deruxtecan (T-DXd) reshaping treatment across early-stage and metastatic HER2-positive breast cancer?Dr. Sarah Premji, Dr. Reshma Mahtani, and Dr. Eleftherios "Terry" Mamounas discuss the practice-changing implications of DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09, exploring how T-DXd is moving earlier in the treatment paradigm and influencing decision-making from the neoadjuvant setting through first-line metastatic disease. The conversation examines pathologic complete response (pCR), residual disease management, toxicity monitoring, multidisciplinary care, and the evolving role of biomarkers in treatment personalization.Topics include:• DESTINY-Breast11 and neoadjuvant T-DXd strategies• Pathologic complete response (pCR) and treatment de-escalation• Residual disease management after neoadjuvant therapy• DESTINY-Breast05 and adjuvant T-DXd in high-risk disease• Monitoring and managing interstitial lung disease (ILD)• Patient education, supportive care, and toxicity mitigation• Multidisciplinary collaboration in HER2-positive breast cancer care• DESTINY-Breast09 and first-line metastatic treatment advances• T-DXd plus pertuzumab in metastatic HER2-positive disease• Future roles for ctDNA and biomarker-guided treatment decisionsAs HER2-directed therapies continue to evolve, clinicians are increasingly challenged to determine when to introduce the most effective treatments, how to manage long-term toxicities, and how to personalize care across the entire disease continuum.Watch more expert oncology discussions from Community Health Media and subscribe for future conversations with leading oncology experts.

Dr. Jason Mouabbi, Dr. Fenting Yan, & Dr. Paolo Tarantino - First-Line T-DXd in HER2+ mBC

Can T-DXd plus pertuzumab finally replace the CLEOPATRA regimen as the new first-line standard for metastatic HER2-positive breast cancer?In this comprehensive discussion from ASCO 2026, Dr. Jason Mouabbi, Dr. Fengting Yan, and Dr. Paolo Tarantino break down the practice-changing DESTINY-Breast09 data and what it means for treatment sequencing, patient selection and toxicity management. Beyond the clinical trial results, the experts share their perspectives on the evolving therapeutic landscape—specifically, the future possibility of achieving cures in metastatic HER2-positive breast cancer.The panel explores why antibody-drug conjugates are moving earlier in treatment, the impressive progression-free survival results from DESTINY-Breast09, the significance of deep partial responses, and how clinicians should think about treatment duration, maintenance strategies, and long-term disease control.Topics discussed include:• DESTINY-Breast09 study design and results• T-DXd plus pertuzumab vs CLEOPATRA (THP)• Progression-free survival and response outcomes• Deep partial response vs complete response• Attrition rates and why first-line therapy matters• ILD monitoring and management strategies• Nausea, fatigue, and alopecia management• Olanzapine for T-DXd-associated nausea• PIK3CA-mutated HER2-positive disease• PATINA and HER2CLIMB-05 implications• Maintenance therapy considerations• Rechallenging T-DXd after recurrence• ADC sequencing in metastatic HER2-positive breast cancer• The possibility of cure in metastatic HER2-positive diseaseAs treatment options continue to evolve, understanding how to maximize the benefits of T-DXd while managing toxicity will be critical for improving outcomes in HER2-positive metastatic breast cancer.Subscribe for more expert oncology discussions, breast cancer treatment updates, and ASCO 2026 coverage.